Skip to main content

Advertisement

Table 3 Summary of meta-analysis outcomes for Japanese type 2 diabetes patients with low (<25 kg/m2) and high (≥25 kg/m2) baseline body mass index (BMI)

From: Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis

Outcome Effect estimate 95 % Confidence limits p value Effect estimate 95 % Confidence limits p value
Lower Upper Lower Upper
Low (<25 kg/m2) baseline BMI High (≥25 kg/m2) baseline BMI
Change in HbA1c (%) −0.88 −1.21 −0.55 <0.0001 −1.28 −1.81 −0.75 <0.0001
Change in weight (kg) −0.38 −1.07 0.32 0.29 −0.28 −1.18 0.61 0.53
Change in FPG (mg/dL) −5.9 −19.1 7.5 0.39 −21.2 −45.8 3.5 0.09
Change in PPG: meal: test (mg/dL) −147.9 −178.6 −117.3 <0.0001 −151.5 −178.8 −124.3 <0.0001
  1. FPG fasting plasma glucose, PPG postprandial glucose
  Odds ratio 95 % Confidence limits p value Odds ratio 95 % Confidence limits p value
Lower Upper Lower Upper
Low (<25 kg/m2) baseline BMI High (≥25 kg/m2) baseline BMI
Symptomatic hypoglycemia 2.8 1.1 7.0 0.0270 4.2 1.1 15.7 0.0362
Severe hypoglycemia 0.0 0.0 0.0 0.0 0.0 0.0
Endpoint HbA1c <7 % 11.2 3.2 39.7 0.0002 23.6 3.0 183.6 0.0025
Endpoint HbA1c <7 % and no weight gain 7.6 2.1 27.9 0.0024 16.2 2.1 127.2 0.0083
Endpoint HbA1c <7 % and no symptomatic hypoglycemia 9.6 2.1 43.7 0.0036 15.6 2.0 123.7 0.0093
Endpoint HbA1c <7 % and no weight gain and no symptomatic hypoglycemia 7.4 1.6 32.2 0.0114 9.5 1.2 77.7 0.0356
  1. FPG fasting plasma glucose, PPG postprandial glucose